• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » NicoDerm CQ

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

NicoDerm CQ

  • Profile

Profile

Contact Information

Currently Enrolling Trials

    Show More

    General Information

    NicoDerm CQ has been approved as an OTC stop smoking aid. NicoDerm CQ is the first OTC nicotine patch to be available in all prescription strengths: 21 mg, 14 mg, and 7 mg per day. NicoDerm CQ provides a step down program that allows smokers to gradually reduce their nicotine intake, rather than stop abruptly. Most smokers should start with Step 1 (21 mg) for six weeks; step down to Step 2 (14 mg) for two weeks; and then use Step 3 (7 mg) for two weeks.

    NicoDerm CQ is the only nicotine patch approved for light smokers. Those who smoke 10 or fewer cigarettes a day should start with the Step 2 (14 mg) dose for six weeks and then step down to the Step 3 (7 mg) dose for two weeks.

    NicoDerm CQ is the only patch that can be worn for either 16 or 24 hours. Smokers who crave cigarettes when they wake up can wear the patch for 24 hours.

    Certain patient populations should seek the advice of a health professional prior to starting therapy with nicotine patches. These include people under the age of 18; people with heart disease, an irregular heart beat, or those who have had a recent heart attack; people with high blood pressure not controlled with medication; people taking prescription medicine for depression or asthma; or people with skin problems or those who are allergic to adhesive tape. Pregnant or nursing women should first try to stop smoking without the nicotine patch and seek the advice of a health professional before using a nicotine patch.

    Side Effects

    The most frequently reported adverse effects associated with nicotine patches are usually mild and include itching or burning at the site of application and dizziness.

    Approval Date: 1996-08-01
    Company Name: SmithKline Beecham, Hoechst Marion Roussel, Alza
    Back to Listings

    Upcoming Events

    • 26Jan

      Reducing Complexity in Starting Clinical Trials – More Patients, Faster Startup

    • 27Jan

      Medical Device Clinical Trials in China: Latest Regulatory Developments

    • 11Feb

      Lab X.0: Addressing Quality and Compliance Challenges in Laboratory Operations in the COVID-19 All-Digital Era

    • 23Mar

      Data Integrity for GCP Professionals: Core Requirements, Expectations and Challenges

    • 26Apr

      MAGI's Clinical Research vConference — Spring 2021

    Featured Products

    • Regenerative Medicine – Steps to Accelerate Development : PDF

      Regenerative Medicine: Steps to Accelerate Development

    • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

      Clinical Trial Agreements: A Guide to Key Words and Phrases

    Featured Stories

    • TechInnovation-360x240.png

      Pace of Technology Innovation in Trials Could Slow After Pandemic Eases

    • AskTheExperts-360x240.png

      Ask the Experts: Certifying and Maintaining Copies of Original Source Documents

    • Resources-360x240.png

      Trial Complexity, Endpoints Continue to Increase, Stretching Site Resources

    • FocusinRed-360x240.png

      Return to Focus on Risk Management Postpandemic Could Prove Challenging to Sites

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell My Personal Information

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing